Induction therapy in renal transplant recipients: How convincing is the current evidence?

Steven J. Wagner, Daniel C. Brennan

Research output: Contribution to journalReview articlepeer-review

Abstract

The goal of orntibodies specific for multiple adhesion molecules and even human leukocyte antigen, while CD52 (the target of alemtuzumab) is present on many antigen-presenting cells as well as lymphocytes. The manner in which the immune system recovers after induction may also aid in establishment of immune tolerance, with proliferation of suppressor T lymphocytes seen with rATG use. The various contributions of these mechanisms in achieving the goal of allograft tolerance are currently being investigated. The currently available data are of generally low quality, based on many small and often retrospective studies. Definitions of 'high risk' vary between studies, as do induction and maintenance dosing regimens. Standardization of definitions and establishment of large, prospective, multicentre trials would lead to a better understanding of the currently available agents and their best use in renal transplantation induction therapy.

Original languageEnglish (US)
Pages (from-to)671-683
Number of pages13
JournalDrugs
Volume72
Issue number5
DOIs
StatePublished - 2012
Externally publishedYes

Keywords

  • Alemtuzumab
  • Antithymocyte-globulin
  • Basiliximab
  • Daclizumab
  • Monoclonal-antibodies
  • Muromonab-CD3
  • Polyclonal-antibodies
  • Renal-transplant
  • Renal-transplant-rejection

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Induction therapy in renal transplant recipients: How convincing is the current evidence?'. Together they form a unique fingerprint.

Cite this